DelveInsight’s Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer: Overview
Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market
Some of the key facts of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Report
- According to DelveInsight’s assessment, in the United States, 7 out of 10 patients had metastatic NSCLC (Stage IIIb and IV).
- DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.
- Among the European 5 countries, the Germany had highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Treatment Market
There are several treatment options available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market Insights
The market for EGFR NSCLC is estimated to grow at a CAGR of 14.9% for the period 2019-2032. According to DelveInsight’s estimates, the total market size for EGFR-NSCLC is expected to grow in the seven major markets, which will contribute to the total market size of NSCLC.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Epidemiology
The epidemiology section covers insights about the historical and current Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market or expected to get launched in the market during the study period. The analysis covers Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Emerging Therapies
The available therapeutics treatment options in EGFR-NSCLC Landscape aims to provide cure to the patients suffering from this indication, however there are several challenges which are yet to be tackled.
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Companies
- AstraZeneca
- Pfizer
- Takeda
- Janssen
- Novartis Pharmaceuticals
- Abbvie
- Daiichi Sankyo
- Yuhan Corporation/ Janssen Research & Development, and Others
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Drugs
- Lazertinib
- Patritumab Deruxtecan (HER3-DXd)
- Telisotuzumab Vedotin (Teliso-V)
- Nazartinib (EGF816)
- Rybrevant (amivantamab-vmjw)
- Exkivity (Mobocertinib)
- Vizimpro (Dacomitinib)
- Tagrisso (Osimertinib), and Others
Read Full Research Report @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/